Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | AHR | P35869 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | ALPL | P05186 | 1/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.50 |
| ▸ | KMO | O15229 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117667 | 0.87 | MARS1 (0.60) | NPC1RAB9ANR1I2AHRSMN1; SMN2 | |
| SCHEMBL70360 | 0.86 | CA12 (0.53) | CA12ALPLMAPTMEN1KMT2A | |
| SCHEMBL8860019 | 0.85 | MKNK1 (0.57) | NPC1RAB9ANR1I2AHRSMN1; SMN2 | |
| SCHEMBL29019950 | 0.84 | MEN1 (0.51) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL16103962 | 0.84 | NR4A2 (0.56) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL69492 | 0.84 | MEN1 (0.58) | NPC1RAB9ASMN1; SMN2ALPLMAPT | |
| SCHEMBL3682308 | 0.83 | KMO (0.55) | MAPTMEN1KMT2APOLBKMO | |
| SCHEMBL19996893 | 0.83 | MEN1 (0.50) | CA12ALPLMAPTMEN1KMT2A | |
| SCHEMBL1413865 | 0.83 | ALPL (0.53) | SMN1; SMN2MKNK1MKNK2ALPLMAPT | |
| SCHEMBL1413926 | 0.83 | MEN1 (0.54) | MAPTMEN1KMT2APOLBMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869953-B2 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2005-03-22 | — | — | US | claimed |
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HAAG RAINER (DE) | 2004-09-30 | — | — | US | claimed |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2003-07-24 | — | — | US | claimed |
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-7947717-B2 | Inhibitors of lethal factor protease | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947717-B2 | Inhibitors of lethal factor protease | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2291372-A2 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | Burnham Institute for Medical Research (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20100016313-A1 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016313-A1 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016292-A1 | INHIBITORS OF LETHAL FACTOR PROTEASE | THE BURNHAM INSTITUTE (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016292-A1 | INHIBITORS OF LETHAL FACTOR PROTEASE | THE BURNHAM INSTITUTE (US) | 2010-01-21 | — | — | US | disclosed |
| CN-1268614-C | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 2006-08-09 | — | — | CN | disclosed |
| CN-1699347-A | Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation | SEARLE & CO (US) | 2005-11-23 | — | — | CN | disclosed |
| CN-1495170-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | G.D.ɪ����˾ | 2004-05-12 | — | — | CN | disclosed |
| CN-1134418-C | Substituted pyrazolyl benzenesulfonamides for treating inflammation | - | 2004-01-14 | — | — | CN | disclosed |
| CN-1127484-C | Substituted pyrazolyl benzene sulfone amides compounds for curing inflammation | SEARLE & CO (US) | 2003-11-12 | — | — | CN | disclosed |
| CN-1280126-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 2001-01-17 | — | — | CN | disclosed |
| CN-1280125-A | Substituted pyrazolyl benzene sulfone amides compounds for curing inflammation | SEARLE & CO (US) | 2001-01-17 | — | — | CN | disclosed |
| CN-1202828-A | Substituted pyrzolyl benzenesulfonanides for use in veterinary | SEARLE & CO (US) | 1998-12-23 | — | — | CN | disclosed |
| CN-1141630-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 1997-01-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | NPC1 71/4885RAB9A 2425/4885NR1I2 277/4885 |
| US-20100016313-A1 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | ALPI, SI, FABP2 | NPC1 1539/4885RAB9A 1635/4885NR1I2 3918/4885 |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | NPC1 71/4885RAB9A 2425/4885NR1I2 277/4885 |
| US-20100016292-A1 | INHIBITORS OF LETHAL FACTOR PROTEASE | APAF1, F11, SERPINB1 | NPC1 2786/4885RAB9A 1485/4885NR1I2 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.